Map Global Reimbursement & Coverage Landscape, Perform Primary Research with Payers to Inform Trial Design & Go No Go Decisions.
Planning for evidence generation and synthesis to support economic models must therefore start early in product development.
Quantitative research into treatment, disease burden, and resource use to inform multiple elements of the market access strategy.
Identify & Engage all relevant KOLs and Payers around the globe based on tailored segmentation criteria with a Digital Interface.
Disrupt or be disrupted, Explore Game Changing Innovation Based on Predictive Analytics and Design Thinking. Scout Innovation more effectively, expand your global reach.
Explore strategies to optimize patient-reported outcomes to support the value proposition to regulators, reimbursement agencies, and patients.
Transform Market Access & Reach Payer Decision Makers.
PRA™ is a strategic planning tool designed to evaluate the planned and required evidence for your product on a country-by-country basis.
Maximize commercial Value with Real world Evidence
Our clients include over 20% of the 50 largest life science companies in the world by market capitalization, we’re also behind the success of many smaller category leaders across a broad range of therapeutic areas.
Outlined below is a video describing real world evidence.